image
Healthcare - Medical - Devices - NASDAQ - US
$ 27.34
-4.37 %
$ 1.8 B
Market Cap
-14.62
P/E
1. INTRINSIC VALUE

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin.[ Read More ]

The intrinsic value of one TNDM stock under the base case scenario is HIDDEN Compared to the current market price of 27.3 USD, Tandem Diabetes Care, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TNDM

image
FINANCIALS
748 M REVENUE
-6.68%
-233 M OPERATING INCOME
-277.34%
-223 M NET INCOME
-135.33%
-31.8 M OPERATING CASH FLOW
-63.04%
-85.7 M INVESTING CASH FLOW
-258.50%
4.11 M FINANCING CASH FLOW
-75.63%
363 M REVENUE
63.71%
-26.1 M OPERATING INCOME
15.21%
-23.3 M NET INCOME
24.54%
26.8 M OPERATING CASH FLOW
607.66%
-19.9 M INVESTING CASH FLOW
-462.03%
-4.52 M FINANCING CASH FLOW
-50.53%
Balance Sheet Decomposition Tandem Diabetes Care, Inc.
image
Current Assets 748 M
Cash & Short-Term Investments 468 M
Receivables 106 M
Other Current Assets 175 M
Non-Current Assets 205 M
Long-Term Investments 32.4 M
PP&E 164 M
Other Non-Current Assets 7.94 M
Current Liabilities 195 M
Accounts Payable 49.6 M
Short-Term Debt 34.1 M
Other Current Liabilities 112 M
Non-Current Liabilities 444 M
Long-Term Debt 399 M
Other Non-Current Liabilities 45.2 M
EFFICIENCY
Earnings Waterfall Tandem Diabetes Care, Inc.
image
Revenue 748 M
Cost Of Revenue 380 M
Gross Profit 368 M
Operating Expenses 601 M
Operating Income -233 M
Other Expenses -10.6 M
Net Income -223 M
RATIOS
49.17% GROSS MARGIN
49.17%
-31.19% OPERATING MARGIN
-31.19%
-29.77% NET MARGIN
-29.77%
-70.98% ROE
-70.98%
-23.37% ROA
-23.37%
-38.28% ROIC
-38.28%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tandem Diabetes Care, Inc.
image
Net Income -223 M
Depreciation & Amortization 15.7 M
Capital Expenditures -51.6 M
Stock-Based Compensation 88.1 M
Change in Working Capital -17.7 M
Others 134 M
Free Cash Flow -83.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tandem Diabetes Care, Inc.
image
Wall Street analysts predict an average 1-year price target for TNDM of $48.9 , with forecasts ranging from a low of $36 to a high of $75 .
TNDM Lowest Price Target Wall Street Target
36 USD 31.68%
TNDM Average Price Target Wall Street Target
48.9 USD 79.02%
TNDM Highest Price Target Wall Street Target
75 USD 174.32%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Tandem Diabetes Care, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
258 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
94.8 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
5 months ago
May 30, 2024
Sell 258 K USD
Allen Dick
Director
- 5000
51.68 USD
11 months ago
Nov 27, 2023
Bought 94.8 K USD
Allen Dick
Director
+ 5000
18.9555 USD
1 year ago
Nov 08, 2023
Bought 95.4 K USD
Vosseller Leigh
EVP & CHIEF FINANCIAL OFFICER
+ 6200
15.3863 USD
1 year ago
Nov 08, 2023
Bought 29.9 K USD
Hansen Shannon Marie
Chief Legal Officer
+ 1935
15.4441 USD
1 year ago
Sep 15, 2023
Bought 21.4 K USD
McGroddy-Goetz Kathleen
Director
+ 1000
21.45 USD
1 year ago
May 18, 2023
Bought 295 K USD
Allen Dick
Director
+ 10000
29.4687 USD
1 year ago
May 17, 2023
Bought 90.5 K USD
Howell Peyton R
Director
+ 3000
30.164 USD
1 year ago
May 12, 2023
Bought 98.8 K USD
Vosseller Leigh
EVP & CHIEF FINANCIAL OFFICER
+ 3015
32.7713 USD
1 year ago
Mar 03, 2023
Sell 412 K USD
BERGER DAVID B
EVP & Chief Operating Officer
- 10000
41.1884 USD
1 year ago
Dec 16, 2022
Sell 402 K USD
BERGER DAVID B
EVP & Chief Operating Officer
- 10000
40.25 USD
7. News
TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi. zacks.com - 1 week ago
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript seekingalpha.com - 1 week ago
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 week ago
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.38 per share a year ago. zacks.com - 1 week ago
Tandem Diabetes Care Announces Upcoming Conference Participation SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a company update at the following investor conferences: UBS Global Healthcare Conference on Thursday, November 14, 2024 at 11:45am Eastern Time (8:45am Pacific Time), Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 11:30am Eastern Time (8:30am Pacific Time), Jefferies London Healthcare. businesswire.com - 2 weeks ago
Down -21.69% in 4 Weeks, Here's Why Tandem Diabetes Care (TNDM) Looks Ripe for a Turnaround Tandem Diabetes Care (TNDM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com - 4 weeks ago
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. TNDM, a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. benzinga.com - 1 month ago
Why Tandem Diabetes Care Stock Took It on the Chin Tuesday Flat revenue growth might be in store for the company in a very crucial market. fool.com - 1 month ago
t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality. zacks.com - 1 month ago
TNDM Stock Likely to Gain From Innovation Amid Competition Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition. zacks.com - 1 month ago
TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union. zacks.com - 1 month ago
Why Tandem Diabetes Care Stock Thrashed the Market Today It earned a regulatory nod in one of the largest markets in the world. Approval was granted for a system to deliver an ultra-rapid insulin product developed by Eli Lilly. fool.com - 1 month ago
8. Profile Summary

Tandem Diabetes Care, Inc. TNDM

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.8 B
Dividend Yield 0.00%
Description Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Contact 11075 Roselle Street, San Diego, CA, 92121 https://www.tandemdiabetes.com
IPO Date Nov. 14, 2013
Employees 2400
Officers Mr. John F. Sheridan President, Chief Executive Officer & Director Mr. David B. Berger Esq. Transitional Advisor Dr. Jordan Pinsker M.D. Chief Medical Officer Mr. Mark Novara Executive Vice President & Chief Commercial Officer Mr. Jean-Claude E. Kyrillos Executive Vice President & Chief Operating Officer Mr. Rick A. Carpenter Chief Technical Officer Mr. Tom Fox Chief Human Resources Officer Ms. Elizabeth Anne Gasser Executive Vice President and Chief Strategy & Product Officer Ms. Leigh A. Vosseller Executive Vice President, Chief Financial Officer & Treasurer Ms. Susan M. Morrison Executive Vice President & Chief Administrative Officer